Halozyme Therapeutics to Present New Data on the Company's Ultrafast Insulin Programs at ADA 2012
SAN DIEGO, June 1, 2012 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the Company will present data from its diabetes studies for both multiple daily injections (MDI) and continuous subcutaneous insulin infusion (CSII) Ultrafast Insulin programs at the 72nd Scientific Sessions of the American Diabetes Association (ADA) being held in Philadelphia, PA from June 8 – 12.
The annual meeting of the ADA is the largest scientific meeting for endocrinologists and other health care professionals involved in diabetes research and diabetes care. Halozyme will present data through one oral presentation and three posters, including one late-breaker, at the meeting. The data will provide key insights into the scientific basis and clinical utility of the Company's recombinant human hyaluronidase (rHuPH20) enzyme when paired with rapid analog insulins.
"We are pleased to be presenting study results that highlight the potential of ultrafast analog insulins in different clinical settings. rHuPH20 with analog insulins may provide a more consistent profile and reduce troublesome glucose swings. The goal is tighter glucose control and, ultimately, better management of the disease," said Gregory I. Frost, Ph.D., President and Chief Executive Officer, Halozyme. "This meeting attracts some of the most innovative thinkers in the diabetes community. We look forward to participating in conversations and presentations that are united in the goal of improving treatment options for people living with diabetes."
Halozyme Abstracts Being Presented at ADA
1. Oral Presentation (353-OR): "Human Hyaluronidase + Rapid Analog Insulin (RAI) Improves Postprandial Glycemic Control in Type 1 Diabetes (T1DM) Compared to Insulin Lispro Alone" will be presented by Irl B. Hirsch, M.D., University of Washington School of Medicine on Monday, June 11 at 6:15 PM ET.
2. Late Breaking Poster (34-LB): "Initial Clinical Experience with Hyaluronidase Preadministration in the Treatment of Type 1 Diabetes by Sensor Augmented Analog Insulin Pump Therapy" will be presented by Douglas B. Muchmore, M.D., Halozyme Therapeutics during a poster session on Sunday, June 10 from 12:00 – 2:00 PM ET.
3. Poster (882-P): "Human Hyaluronidase + Rapid Analog Insulin (RAI) Improves Postprandial Glycemic Control in Type 2 Diabetes (T2DM) Compared to Insulin Lispro Alone" will be presented by Richard M. Bergenstal, M.D., International Diabetes Center during an audio guided tour on Saturday, June 9 from 12:30 – 1:30 PM ET and during a poster session on Sunday, June 10 from 12:00 – 2:00 PM ET.
4. Poster (905-P): "Human Hyaluronidase (rHuPH20) Provides Consistent Ultrafast Insulin Absorption and Action Over 3 Days of Continuous Subcutaneous Infusion" will be presented by Daniel E. Vaughn, Ph.D., Halozyme Therapeutics during a poster session on Sunday, June 10 from 12:00 – 2:00 PM ET.
Halozyme Therapeutics is a biopharmaceutical company dedicated to developing and commercializing innovative products that advance patient care. With a diversified portfolio of enzymes that target the extracellular matrix, the Company's research focuses primarily on a family of human enzymes, known as hyaluronidases, that increase the absorption and dispersion of biologics. Halozyme's pipeline addresses therapeutic areas, such as diabetes, oncology and dermatology that have significant unmet medical need. The Company markets Hylenex® recombinant (hyaluronidase human injection) and has partnerships with Roche, Baxter, ViroPharma and Intrexon. Halozyme is headquartered in San Diego, CA. For more information on how we are innovating, please visit our corporate website at www.halozyme.com.
Safe Harbor Statement
In addition to historical information, the statements set forth above include forward-looking statements (including, without limitation, statements concerning the timing, scope and outcomes of our clinical trials as well as expected activities under our collaborative partnerships) that involve risk and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are also identified through use of the words "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a result of several factors, including clinical trial enrollment and results, regulatory approval requirements and competitive conditions. These and other factors that may result in differences are discussed in greater detail in the company's reports on Forms 10-K, 10-Q, and other filings with the Securities and Exchange Commission.
SOURCE Halozyme Therapeutics, Inc.
Source: PR Newswire (http://s.tt/1d9Yv)
Posted: June 2012